Aviado · Research
Longevity Daily
Wednesday, May 13, 2026
Listen
Today's Brief
Today's most significant finding comes from Nature Aging: a new compound inspired by spinal disc cells extends mouse lifespan by up to 14%, pointing to a druggable pathway in aging biology that no one was watching. Three supplement staples—omega-3s, high-dose B vitamins, and NAD+ infusions—face hard scrutiny in today's evidence-check stories. On the brain side, Science/AAAS reframes dementia as a multi-disease problem, while new research links disrupted sleep to failing amyloid-clearing brain cells. Rounding out the issue: striking GLP-1 cancer survival data and a high-stakes trial now testing rapamycin, semaglutide, and dapagliflozin as human longevity drugs.
10 stories1 peer-reviewed1 trials
Cognitive Health & Neuroprotection
Most Dementia Patients Have Multiple Brain Diseases at Once—and That Changes Everything
A Science/AAAS deep-dive challenges the prevailing single-disease model of dementia, finding that most patients simultaneously harbor amyloid plaques, Lewy bodies, TDP-43 deposits, and other co-pathologies. This complicates treatment: drugs targeting one pathway (like amyloid-clearing antibodies) may leave the bigger picture untouched. An upcoming trial—the first ever designed around a co-pathology—will test donanemab in patients who have both Alzheimer's amyloid and Lewy body disease, representing a meaningful shift in how the field is approaching treatment.
Read more →Disrupted Sleep Puts Your Brain's Clean-Up Crew Out of Commission
New research from Neuroscience News shows that when circadian rhythms are disrupted, microglia—the brain's specialized immune cells—enter a "stress-primed" state that prevents them from clearing amyloid plaques, the hallmark deposits of Alzheimer's disease. The finding provides a mechanistic link between poor sleep and accelerating dementia risk. Scientists are now testing an extracellular vesicle (EV) therapy to restore microglial function using DARI seedling grant funding, though human applications remain early-stage.
Read more →Supplements & Compounds
NAD+ Pills and Infusions Are Everywhere. Here's What the Evidence Actually Says.
Washington University School of Medicine takes a hard look at the booming NAD+ longevity market—NMN capsules, NR supplements, and IV infusions—asking what clinical evidence actually supports the claims. The short answer: preclinical data is promising, but human trials remain limited, short-term, and mixed. If you're spending significantly on NAD+ products, this is a useful reality check from a credible academic source.
Read more →High-Dose B6 and B12 Supplements May Raise Lung Cancer Risk in Some People
ScienceAlert rounds up expert commentary on a nuanced but important signal: some observational research links long-term, high-dose B6 and B12 supplementation to a slight increase in lung cancer risk, particularly in men and smokers. B vitamins are water-soluble and widely assumed to be harmless in large quantities, making this a useful challenge to the "more is better" supplement assumption. Observational studies cannot prove causation, and B vitamins at standard dietary levels appear safe—but the data is a meaningful flag for anyone stacking high-dose B-complex products.
Read more →Fish Oil and Faster Cognitive Decline? A New Study Raises Red Flags—With Important Caveats
An observational study comparing 273 regular omega-3 supplement users with 546 matched non-users found that fish-oil takers appeared to decline faster on several cognitive scores—a result that directly contradicts the conventional wisdom around fish oil and brain health. The study's own author still takes fish oil, noting that reverse causation is the most likely explanation: people noticing early cognitive changes may self-select into supplement use. The evidence on omega-3s and brain health remains genuinely mixed, and this study is a well-timed prompt to reassess uncritical "fish oil is always protective" thinking.
Read more →Research & Papers
Spinal Disc Cells Age Slowly for a Reason—and Scientists Just Turned That Mechanism Into a Drug
Intervertebral discs—the cushions between vertebrae—age remarkably slowly compared to other tissues, and researchers at Nature Aging finally know why. These cells possess a unique ability to degrade the protein HIF-1α even under low-oxygen conditions, preventing cellular stress that drives aging. The team developed a small molecule called HATC that exports this mechanism to other tissues; in aged mice, weekly systemic injections reduced age-related pathology across multiple organs and extended median lifespan by ~14% and maximum lifespan by ~12%. This is a mouse study and HATC is years from human trials, but it identifies a compelling new druggable target in the core biology of aging—one that appears to be distinct from existing approaches like rapamycin or senolytics.
Read more →GLP-1 Drugs Show Striking Survival Advantage in Breast Cancer Patients
A new study reported by News-Medical finds that breast cancer patients taking GLP-1 receptor agonists had dramatically better all-cause survival: 96.9% at five years in the GLP-1 group versus 82.3% in those on insulin or metformin—and the gap widened to 96.9% vs. 76.4% at ten years. The finding adds to a growing body of evidence that GLP-1 drugs may carry cancer-protective effects beyond weight loss. This is observational data, and healthy user bias (GLP-1 patients may have been healthier at baseline) cannot yet be ruled out.
Read more →Lifestyle & Nutrition
Four Weeks of Dietary Shifts Can Make Older Adults Measurably Younger—Biologically
Researchers at the University of Sydney, publishing in Aging Cell, found that older adults who shifted to a low-fat, plant-forward eating pattern for just four weeks showed measurable reductions in biological age markers. The finding challenges the assumption that meaningful biological age changes require sustained, years-long interventions. Sample size and methodology details warrant scrutiny, but the core implication—that biological age clocks are more plastic and responsive to diet than previously appreciated—is compelling.
Read more →Can You Stand From a Chair Without Using Your Hands? It May Predict How Long You'll Live
New research finds that grip strength and the ability to rise from a chair without arm support are powerful predictors of longevity in older women, with greater functional muscle strength linked to significantly lower mortality risk. These zero-cost tests—which you can perform right now—are increasingly validated as proxies for overall metabolic, cardiovascular, and musculoskeletal health. The findings reinforce resistance training and functional strength work as longevity investments, not merely cosmetic ones.
Read more →Industry & Policy
Rapamycin, Semaglutide, and Dapagliflozin Are Now Being Tested Together as Human Longevity Drugs
A new longevity trial is testing three already-approved drugs—rapamycin (an mTOR inhibitor), dapagliflozin (an SGLT2 inhibitor), and semaglutide (the GLP-1 behind Ozempic/Wegovy)—for their potential to slow human aging. USC gerontologist Sean Curran notes that all three compounds have extended lifespan in organisms ranging from yeast to mammals, and the trial represents a pragmatic pivot: testing widely available drugs rather than waiting for novel geroprotective molecules. Early results will be closely watched by the longevity field.
Read more →